Role of tumour necrosis factor (TNF)-α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis

Clinical and Experimental Immunology

Volumn 166, Issue 3, 2011, Pages 338-345

  Caminero, A ^a,b   Comabella, M ^a   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Hospital Provincial   (Spain)

Author keywords

Genetic factors; Multiple sclerosis; TNF; TNFR1; TNFRSF1A R92Q mutation

Indexed keywords

CYTOKINE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED SUPERFAMILY MEMBER 1A; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BEHAVIOR CHANGE; DISEASE COURSE; DISEASE SEVERITY; ENCEPHALITIS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; HEADACHE; HUMAN; MEMORY DISORDER; MENINGITIS; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; OPTIC NEURITIS; PAPILLITIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

GENOME-WIDE ASSOCIATION STUDY; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80855144615     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04484.x     Document Type: Article

References (69)

1. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991; 38:1-15.
2. Barcellos LF, Sawcer S, Ramsay PP etal. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006; 15:2813-24.
3. De Jager PL, Jia X, Wang J etal. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41:776-82.
4. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science 1997; 278:1580-1.
5. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9:516-26.
6. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17:331-67.
7. Kluger MJ, Kozak W, Leon LR, Soszynski C, Conn CA. Cytokines and fever. Neuroimmunomodulation 1995; 2:216-23.
8. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008; 5:1-13.
9. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Annu Rev Immunol 1989; 7:625-55.
10. Naismith JH, Devine TQ, Kohno T, Sprang SR. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure 1996; 4:1251-62.
11. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Leonardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288:2351-4.
12. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 1998; 95:570-5.
13. Tracey D, Klareskog L, Sasso EJ, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244-79.
14. Yang L, Lindholm K, Konishi Y, Li R, Shen Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 2002; 22:3025-32.
15. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129:1953-71.
16. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170:607-12.
17. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325:467-72.
18. Rieckmann P, Albrecht M, Kitze B etal. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995; 37:82-8.
19. Kassiotis G, Pasparakis M, Kollias G, Probert L. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur J Immunol 1999; 29:774-80.
20. Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001; 11:107-16.
21. Probert L, Eugster HP, Akassoglou K etal. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 2000; 123:2005-19.
22. Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001; 193:427-34.
23. Suvannavejh GC, Lee HO, Padilla J, Dal Canto MC, Barret TA, Miller SD. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG (35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol 2000; 205:24-33.
24. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alfa promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4:1116-22.
25. Hull KM, Drewe E, Aksentijevic I etal. The TNF receptor-associated periodic syndrome (TRAPS). Emerging concepts of an autoinflammatory disorder. Medicine 2002; 81:349-68.
26. Aganna E, Hammond L, Hawkins PN etal. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003; 48:2632-44.
27. Gertz MA, Petitt RM, Perrault J, Kyle RA. Autosomal dominant familial Mediterranean fever-like syndrome with amyloidosis. Mayo Clin Proc 1987; 62:1095-100.
28. McDermott EM, Smillie DM, Powell RJ. Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. Mayo Clin Proc 1997; 72:806-17.
29. Church LD, Churchman SM, Hawkins PN, McDermott MF. Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol 2006; 27:494-508.
30. Touitou I, Lesage S, McDermott M etal. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat 2004; 24:194-8.
31. McDermott MF, Aksentijevich I, Galon J etal. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndrome. Cell 1999; 97:133-44.
32. Kimberley FC, Lobito AA, Siegel RM, Screaton GR. Falling into TRAPS-receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 2007; 9:1-8.
33. Galon J, Aksentijevich I, McDermott MF, O'Shea JJ, Kastne DL. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000; 12:479-86.
34. Aksentijevich I, Galon J, Soares M etal. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69:301-14.
35. Ravet N, Rouaghe S, Dodé C etal. Clinical significance of P46L and R92Q substitutions in the tumor necrosis factor superfamily 1A gene. Ann Rheum Dis 2006; 65:1158-62.
36. Tchernitchko D, Chiminqgi M, Galactéros F etal. Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations. Eur J Hum Genet 2005; 13:513-5.
37. Gattorno M, Sormani MP, D'Osualdo A etal. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008; 58:1823-32.
38. Lobito AA, Kimberley FC, Muppidi JR etal. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in the TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108:1320-7.
39. Aksentijevich I, Nowak M, Mallah M etal. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46:3340-8.
40. Dodé C, André M, Bienvenu T etal. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002; 46:2181-8.
41. Simon A, Park H, Maddipati R etal. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci USA 2010; 25:9801-6.
42. Rebelo SL, Bainbridge SE, Amel-Kashipaz MR etal. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 2006; 54:2674-87.
43. Todd I, Radford PM, Daffa N, Bainbridge SE, Powell RJ, Tighe PJ. Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum 2007; 56:2765-73.
44. D'Osualdo A, Ferlito F, Prigione I etal. Neutrophils from patients with TNFRSF1A mutations display resistance to tumour necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006; 54:998-1008.
45. Sieber F, Fielding CA, Williams BD, Brennan P. Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF-kappaB activation due to decreased surface expression. FEBS Lett 2005; 579:5193-8.
46. Siebert S, Amos N, Fielding CA etal. Reduced tumor necrosis factor signalling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis Rheum 2005; 52:1287-92.
47. Amoura A, Dodé C, Hue S etal. Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease. Arthritis Rheum 2005; 52:608-11.
48. Poirier O, Nicaud V, Gariepy J etal. Polymorphism R92Q of the tumor necrosis factor receptor 1 gene is associated with myocardial infartion and carotid intima-media thickness - the ECTIM, AXA, EVA and GENIC studies. Eur J Hum Genet 2004; 12:213-19.
49. Cantarini L, Lucherini OM, Cimaz R etal. Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunopathol Pharmacol 2009; 22:1051-8.
50. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273:1516-17.
51. Dipple KM, McCabe ER. Phenotypes of patients with 'simple' Mendelian disorders are complex traits: thresholds, modifiers and systems dynamics. Am J Hum Genet 2000; 66:1729-35.
52. Rosen-Wolff A, Kreth HW, Hofmann S etal. Periodic fever (TRAPS) caused by mutations in the TNF-alfa receptor 1 (TNFRSF1A) gene of three German patients. Eur J Haematol 2001; 67:105-9.
53. Hurst M, Hull K, Nicholls D, Ameratunga R. Hereditary periodic fever syndrome sans fever or distinct periodicity presenting with psychosis. J Clin Rheumatol 2005; 11:329-30.
54. Rudofsky G, Hoffmann F, Muller K etal. A nephrotic patient with tumor necrosis factor receptor-associated syndrome, IgA nephropathy and CNS involvement. Nephrol Dial Transplant 2006; 21:1109-12.
55. Wildemann B, Rudofsky G Jr, Kress B, Jarius S, Konig F, Schwenger V. The tumor necrosis factor-associated periodic syndrome, the brain, and tumor necrosis factor-alfa antagonists. Neurology 2007; 68:1742-4.
56. Minden K, Aganna E, McDermott MF, Zing A. Tumor necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 2004; 63:1356-7.
57. Hoffmann LA, Lohse P, König FB, Feneberg W, Hohlfeld R, Kümpfel T. TNFRSF1A R92Q mutation in association with a multiple sclerosis-like demyelinating syndrome. Neurology 2008; 70:1155-6.
58. Herndon RM. Multiple sclerosis mimics. Adv Neurol 2006; 98:161-6.
59. Sriram S. TRAPS and MS: two diseases of an MS mimic? Neurology 2008; 70:1077-8.
60. Yahalom G, Kivity S, Lidar M etal. Familial Mediterranean fever (FMF) and multiple sclerosis: an association study in one of the world's largest FMF cohorts. Eur J Neurol 2011; 18:1146-50.
61. Akman-Demir G, Gul A, Gurol E etal. Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): coincidence or association. J Neurol 2006; 253:928-34.
62. Polman CH, Reingold SC, Banwell B etal. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292-302.
63. van Oosten BW, Barkhof F, Truyen L etal. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47:1531-4.
64. Lenercept Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53:457-65.
65. Kümpfel T, Hoffmann LA, Rübsamen H etal. Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. Arthritis Rheum 2007; 56:2774-83.
66. Kauffman MA, Gonzalez-Morón D, Garcea O, Villa AM. TNFSFR1A R92Q mutation, autoinflammatory symptoms and multiple sclerosis in a cohort from Argentina. Mol Biol Rep 2011. doi: 10.1007/s11033-011-0716-3 (Epub ahead of print).
67. Kümpfel T, Hoffmann LA, Pellkofer H etal. Multiple sclerosis and the TNFRSF1A R92Q mutation. Clinical characteristics of 21 cases. Neurology 2008; 71:1812-20.
68. Fukazawa T, Moriwaka F, Hamada K, Hamada T, Tashiro K. Facial palsy in multiple sclerosis. J Neurol 1997; 244:631-3.
69. International Multiple Sclerosis Genetics Consortium, Briggs FB, Shao X, Goldstein BA, Oksenberg JR, Barcillos LF, De Jager PL. Genome-wide association study of severity in multiple sclerosis. Genes Immun 2011; 9 June 2011. doi: 10.1038/gene.2011.34 (Epub ahead of print).